Tivic Health Systems Reports Q2 2025 Earnings, Focuses on Prescription Therapeutics, Secures Exclusive License for TLR5 Agonist Platform, and Strengthens Cash Position.
ByAinvest
Friday, Aug 15, 2025 11:20 am ET1min read
TIVC--
Tivic Health Systems reported Q2 2025 earnings with revenue of $86,000, a gross margin of 63%, and a net loss of $1.9 million. The company plans to exit the consumer health technology business and focus on prescription-based therapeutics. Tivic obtained an exclusive license for Sotero Biopharma's TLR5 agonist portfolio, including late-stage entolimod and Entelaspa candidates. Entolimod has fast track designation for ARS and orphan drug status for pediatric ARS.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet